AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 61 min read$DGX

Catherine T. Doherty to Transition to EVP at Quest Diagnostics, Retirement Set for July 2027

Quest Diagnostics (DGX) announced Catherine T. Doherty will become EVP on November 1, 2026, and retire in July 2027. She will oversee health systems, a joint venture with Corewell Health, and Project Nova. Her base salary remains $650,000, with an $1.2M equity award planned.

Original reporting
tradingview.com
Published Oct 6, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Catherine T. Doherty to Transition to EVP at Quest Diagnostics, Retirement Set for July 2027 — source image
Source · tradingview.com
Decision brief

The 30-second read

$DGXNeutralLow
01

Why it matters

The filing provides a factual update on leadership but does not contain new strategic or financial guidance.

02

Market read

Limited relevance; primarily an informational update for shareholders.

03

What to watch

Potential impact of the Corewell Health JV and Project Nova on future earnings.

Relevance 4/10Novelty 4/10Timing: effective Nov 1 2026

Background

Quest Diagnostics (DGX) disclosed an executive transition via an SEC 8‑K filing.

Company-level read

Ticker impact

$DGXNeutralHigh confidence
Context

Quest Diagnostics filed an 8‑K announcing Catherine T. Doherty's transition to Executive Vice President effective Nov 1 2026 and her retirement in July 2027.

Expected impact

likely neutral as investors await any strategic shifts from the new EVP role

Evidence & confidence

No material compensation change or strategic announcement accompanies the transition; such moves typically do not move the stock significantly.

Market effects

Sector

Minimal; the health‑diagnostics sector sees no immediate change.

Regional

None; the filing is U.S.‑focused.

Global

Low; only relevant to Quest Diagnostics investors.

Counterpoint

What could challenge this read

If the new EVP drives cost‑cutting or new partnerships, the stock could see upside.

Key entities

  • person
    Catherine T. Doherty

    Current executive moving to EVP role, retiring in July 2027

  • company
    Quest Diagnostics Inc.

    U.S. health‑diagnostics firm (ticker DGX)

Read at source← All news

Related articles

OCT 1
$DGXLow

Quest Diagnostics (DGX) Highlights Haystack MRD Test Accuracy in

Quest Diagnostics (DGX) reported high accuracy of its Haystack MRD test in detecting residual and recurrent disease in colorectal cancer and other solid tumors. The study showed 100% sensitivity and specificity at three years, and 83.3% sensitivity at five years. DGX is trading at $233.33, 18.5% above its GF Value™ of $196.83, indicating modest overvaluation.

gurufocus.com3 min
OCT 1
$DGXMed

Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials

Quest Diagnostics' Haystack MRD® test showed 100% specificity and high sensitivity in detecting colorectal cancer recurrence, per a study in The Journal of Molecular Diagnostics. The test, using circulating tumor DNA, outperformed standard biomarkers and validated its performance across 23 solid tumor types. Quest Diagnostics is the provider of the test.

prnewswire.com2 min
SEP 22
$DGXHighAI 8/10

Why Quest Diagnostics Holdings Stock Dropped Today

Quest Diagnostics (DGX) stock fell 5.1% after CMS announced plans to cut lab reimbursement rates by up to 15% starting 2027, affecting 11% of Quest's 2025 revenue. The company had previously warned of such risks in its SEC filing. CMS estimates annual savings of $1 billion from the cuts.

fool.com2 min
SEP 22
$BABAMed

Stocks making the biggest moves premarket: Alibaba, Quest Diagnostics, On Holding, GameStop & more

Alibaba shares rose 3% after its CEO announced plans for 20+ gigawatts of data centers by 2032 and launched a new chip. Quest Diagnostics and Labcorp fell 5% each due to Medicare payment adjustments. Vicor gained 9% on strong Q3 guidance. On Holding jumped 6% after setting new financial targets and a $1B share buyback plan. GameStop rose 3.5% after its CEO bought 1.2M shares.

cnbc.com2 min
SEP 22
$DGXMed

Premarket movers: Quest, Labcorp hit by CMS cuts

U.S. stock index futures steadied on Tuesday. Quest Diagnostics (DGX) fell 6.9% and Labcorp (LH) dropped 4.5% after CMS proposed cuts to lab reimbursements. On Holding (ONON) rose 6.4% on a $1B share buyback plan. Vicor (VICR) surged 9.9% after raising Q3 revenue outlook. Endava (DAVA) fell 12% due to CFO investigation. GameStop (GME) gained 3.5% after CEO bought shares. AnaptysBio (ANAB) rose 3.8% on better-than-expected revenue.

investing.com2 min